DULOXETINE 60 MG
DULOXETINE (DULOXETINE HYDROCHLORIDE) : 60 MG · DIN 02481960 · ALTAMED PHARMA
Health Canada status: MARKETED
What is DULOXETINE?
DULOXETINE 60 MG contains DULOXETINE (DULOXETINE HYDROCHLORIDE) : 60 MG. It is listed in the Health Canada Drug Product Database under DIN 02481960, held by ALTAMED PHARMA, supplied as CAPSULE (DELAYED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Jun-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DULOXETINE used for?
Symptomatic relief of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD); management of pain associated with DPN, Fibromyalgia, Chronic Low Back Pain, and Osteoarthritis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02481960 |
|---|---|
| Brand name | DULOXETINE |
| Generic / active ingredient | DULOXETINE (DULOXETINE HYDROCHLORIDE) : 60 MG |
| Manufacturer | ALTAMED PHARMA |
| Strength | 60 MG |
| Dosage form | CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX21 DULOXETINE |
| AHFS class | 28:16.04.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jun-2026 |
| Original market date | 2023-09-20 00:00:00 |
How is it administered?
Administered orally. MDD: 60 mg once daily. GAD: 60 mg once daily. DPN, FM, CLBP, OA: 60 mg once daily. Gradual dose reduction recommended for discontinuation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists page 52).
How is it supplied?
Not explicitly detailed in provided text (mentions 30 mg and 60 mg strengths).
Contraindications
Hypersensitivity; Concomitant MAOI use; Hepatic impairment; Uncontrolled narrow-angle glaucoma; Severe renal impairment (CrCl <30 mL/min); Thioridazine; Potent CYP1A2 inhibitors.
Warnings and precautions
Potential for behavioral/emotional changes including self-harm; Hepatotoxicity; Increased blood pressure/hypertension; Bone fracture risk; Abnormal bleeding; Serotonin Syndrome risk.
What can be used instead?
Other Canadian products sharing ATC code N06AX21 DULOXETINE. 36 of 66 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-DULOXETINE | 30 MG | CAPSULE (DELAYED RELEASE) | ACCEL PHARMA INC | MARKETED | DIN 02522861 |
| ACCEL-DULOXETINE | 60 MG | CAPSULE (DELAYED RELEASE) | ACCEL PHARMA INC | MARKETED | DIN 02522888 |
| AG-DULOXETINE | 30 MG | CAPSULE (DELAYED RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02475308 |
| AG-DULOXETINE | 60 MG | CAPSULE (DELAYED RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02475316 |
| APO-DULOXETINE | 30 MG | CAPSULE (DELAYED RELEASE) | APOTEX INC | MARKETED | DIN 02440423 |
| APO-DULOXETINE | 60 MG | CAPSULE (DELAYED RELEASE) | APOTEX INC | MARKETED | DIN 02440431 |
| AURO-DULOXETINE | 30 MG | CAPSULE (DELAYED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02436647 |
| AURO-DULOXETINE | 60 MG | CAPSULE (DELAYED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02436655 |
| BIO-DULOXETINE | 30 MG | CAPSULE (DELAYED RELEASE) | BIOMED PHARMA | MARKETED | DIN 02507722 |
| BIO-DULOXETINE | 60 MG | CAPSULE (DELAYED RELEASE) | BIOMED PHARMA | MARKETED | DIN 02507765 |
Who else supplies DULOXETINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DULOXETINE appears in 325 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.